SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10(th )in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on the Company's website, www.novogen.com.
For more information please contact:
Corporate Contact Media enquiries Executive Chairman & CEO In the USA: Novogen Group Graham.Kelly@novogen.com +61 (0) 2 9472 4100 Lazar Partners Novogen@lazarpartners.com +1 212-867-1762 Investors enquiries In Australia: In the USA: Dr. Douglas Pretsell Instinctif Partners Lazar Partners +61 (0) 3 9657 0706 Novogen@lazarpartners.com +1 212-867-1762 In ROW: Sue Charles Instinctif Partners +44 (0) 20 7457 2020
SOURCE Novogen Ltd.